-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022.
-- Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study in China.
-- An epidemiology study in China in 2010 showed that there were approximately 656,000 PBC patients in China including 440,000 in females over age 40. An epidemiology study in the U.S. indicated that there were approximately 120,000 PBC patients in the U.S. in 2014.
Shanghai, China, April 10, 2022-- Gannex Pharma Co., Ltd. (“Gannex”), a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the first patient dosed in the Phase II clinical trial of ASC42 to treat patients with primary biliary cholangitis (PBC).
The Phase II study (ClinicalTrials.gov Identifier: NCT05190523) consists of three ASC42 active treatment arms (5 mg, 10 mg and 15 mg) and one placebo control arm at the ratio of 1:1:1:1 and is expected to enroll a total of 100 patients who have an inadequate response to or are unable to tolerate Ursodeoxycholic acid (UDCA). The treatment duration is 12 weeks and the study is expected to be completed by the end of 2022.
The protocol of Phase III clinical trial in 210 PBC patients was approved in November 2021 by China National Medical Products Administration (NMPA). After the completion of the Phase II clinical trial, Gannex will soon initiate the Phase III trial after the communications with China NMPA in terms of drug registration related matters such as Chemistry, Manufacturing and Control (CMC) and toxicology studies.
ASC42 is an in-house developed, novel non-steroidal, selective, potent Farnesoid X receptor (FXR) agonist with best-in-class potential and global intellectual property. The data from the U.S. Phase I trial of ASC42 indicated there was no pruritus observed during 14-day treatment of the once-daily human therapeutic dose of 15 mg and FXR target engagement biomarker Fibroblast Growth Factor 19 (FGF19) increased 1,780% on Day 14 of treatment with 15 mg dose. Furthermore, mean low density lipoprotein cholesterol (LDL-C) values remained within the normal range during 14-day, once daily treatment with 15 mg.
UDCA is the only drug which is approved in China for PBC and approximately 40% of PBC patients have an inadequate response to or are unable to tolerate UDCA. Obeticholic Acid (OCA), which is not approved in China, is the only approved medicine in the U.S. for PBC patients who have an inadequate response to or are unable to tolerate UDCA. However, there are significantly increased pruritus rates and LDL-C levels in patients with OCA treatment. Absence of pruritus and mean LDL-C values within the normal range at the therapeutic dose makes ASC42 a potential best-in-class PBC drug candidate. Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study in China.
An epidemiology study in China in 2010 showed that there were approximately 656,000 PBC patients in China including 440,000 in females over age 40. An epidemiology study in the U.S. indicated that there were approximately 120,000 PBC patients in the U.S. in 2014.
Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis said, “We are excited ASC42 Phase II trial for PBC is on track. Once again, it demonstrated the execution excellence of our clinical team. We are working very hard to transform ourselves into a global R&D leader in hepatobiliary diseases.”
Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), a global platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, NASH/PBC, and cancer (oral cancer metabolic checkpoint and immune checkpoint inhibitors) to address unmet medical needs both in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis targets those therapeutic areas with unmet medical needs from a global perspective, and efficiently advances the developments of pipelines with an aim of leading in global competition. To date, Ascletis has three marketed products and 20 robust R&D pipelines of drug candidates with global competitiveness, and is actively exploring new therapeutic areas.
1. Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (2) COVID-19 pipeline: currently includes (i) ritonavir oral tablet (100 mg), an authorized product, (ii) ASC10, an oral RNA dependent RNA polymerase (RdRp) inhibitor and (iii) ASC11, an oral 3-chymotrypsin like protease (3CLpro) inhibitor. (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients. (4) Hepatitis C: successfully launched an all-oral regimen of combining ASCLEVIR® and GANOVO® (RDV/DNV regimen).
2. Non-alcoholic Steatohepatitis/Primary Biliary Cholangitis: Gannex, a wholly-owned company of Ascletis, is dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THRβ and FXR, three fixed-dose combinations for NASH and one PBC program targeting FXR.
3. Cancer (oral cancer metabolic checkpoint and immune checkpoint inhibitors): a pipeline of oral inhibitors targeting FASN, which plays a key role in cancer lipid metabolism, and a pipeline of oral PD-L1 small molecule next generation immune checkpoint inhibitors.
4. Exploratory Indications: Acne: Following NASH and recurrent GBM, the third indication for ASC40 has been approved to enter Phase 2 clinical trial. For more information, please visit www.ascletis.com.
Ascletis Pharma Inc.
 Lindor K D, Bowlus C L, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases [J]. Hepatology 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
 Chinese Rheumatology Association (中华医学会风湿病学分会), “Recommendations for diagnosis and treatment of primary biliary cholangitis in China (2021)”(原发性胆汁性胆管炎诊疗规范(2021)) [J]. Zhonghua Nei Ke Za Zhi. (中华内科杂志), 2021, 60(8): 709-15. DOI: 10.3760/cma.j.cn112138-20210520-00360.
 Lu M, Zhou Y, Haller I V, et al. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment [J]. Clin Gastroenterol Hepatol 2018, 16(8): 1342-50 e1. DOI: 10.1016/j.cgh.2017.12.033.